title: Spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients: a randomized controlled trial.
authors.affiliation: National Heart Institute, México City, México.
authors.forename: Armando
authors.initials: A
authors.lastname: Vazquez-Rangel
authors.affiliation: National Heart Institute, México City, México.
authors.forename: Virgilia
authors.initials: V
authors.lastname: Soto
authors.affiliation: National Heart Institute, México City, México.
authors.forename: Marco
authors.initials: M
authors.lastname: Escalona
authors.affiliation: National Heart Institute, México City, México.
authors.forename: Rafael G
authors.initials: RG
authors.lastname: Toledo
authors.affiliation: National Heart Institute, México City, México.
authors.forename: Edgar A
authors.initials: EA
authors.lastname: Castillo
authors.affiliation: National Heart Institute, México City, México.
authors.forename: Nasser Abdel
authors.initials: NA
authors.lastname: Polanco Flores
authors.affiliation: National Heart Institute, México City, México.
authors.forename: Ilse
authors.initials: I
authors.lastname: Falcon-Chavez
authors.affiliation: National Heart Institute, México City, México. Electronic address: madero.magdalena@gmail.com.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Madero
mesh_terms: D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D010530:Peritoneal Dialysis; D056627:Peritoneal Fibrosis / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D012084:Renin-Angiotensin System / Q000187:drug effects; D013148:Spironolactone / Q000627:therapeutic use*
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone